Article citationsMore>>

Sanofi-Aventis (2016) An International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment with Teriflunomide 7 mg Once Daily and 14 mg Once Daily versus Placebo in Patients with a First Clinical Episode Suggestive of Multiple Sclerosis. NCT00622700.

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top